Member Login（https://members.medaus.com.au/）
Policy（https://www.medicinesaustralia.com.au/policy/） Strategic Agreement 2022-2027（https://www.medicinesaustralia.com.au/policy/strategic-agreement-2022-2027/）
Health Technology Assessment (HTA)（https://www.medicinesaustralia.com.au/policy/health-technology-assessment-hta/）
Access to Medicines Working Group (AMWG)（https://www.medicinesaustralia.com.au/policy/access-to-medicines-working-group-amwg/）
Clinical Trials（https://www.medicinesaustralia.com.au/policy/clinical-trials/） Clinical Trial Research Agreements（https://www.medicinesaustralia.com.au/policy/clinical-trials/clinical-trial-research-agreements/）
Indemnity & Compensation Guidelines（https://www.medicinesaustralia.com.au/policy/clinical-trials/indemnity-compensation-guidelines/）
Research & Development Taskforce (RDTF)（https://www.medicinesaustralia.com.au/policy/clinical-trials/research-development-task-force-rdtf/）
Teletrials（https://www.medicinesaustralia.com.au/policy/clinical-trials/tele-trials/）
Oncology Industry Taskforce（https://www.medicinesaustralia.com.au/policy/oncology-industry-taskforce/） Addressing the challenges of access to new cancer medications（https://www.medicinesaustralia.com.au/policy/oncology-industry-taskforce/addressing-the-challenges-of-access-to-new-cancer-medications/）
About the OIT（https://www.medicinesaustralia.com.au/policy/oncology-industry-taskforce/about-the-oit/）
Reports and resources（https://www.medicinesaustralia.com.au/policy/oncology-industry-taskforce/reports-and-resources/）
Pharma Australia Inclusion Group (PAIG)（https://www.medicinesaustralia.com.au/policy/pharma-australia-inclusion-group-paig/）
Policy Submissions（https://www.medicinesaustralia.com.au/policy/submissions/）
Regenerative Medicines Consortium Programme（https://www.medicinesaustralia.com.au/policy/regenerative-medicines-consortium-programme/）
Reforming Australia’s Health Technology Assessment (HTA) System
Medicines Australia is advocating for reform of Australia’s Health Technology Assessment (HTA) system to give Australians faster access to new Pharmaceutical Benefits Scheme (PBS) medicines once they are approved for use by the Therapeutic Goods Administration, now and into the future.
HTA is the process by which medicines are assessed for health benefits and value for money compared to other medicines, before they are recommended for inclusion on the PBS.
The HTA Review Accelerating Access to the Best Medicines for Australians Now and into the Future released in September 2024 found Australia’s system is out-dated and needs urgent reform, with delays to accessing new medicines through the PBS having a profound impact on individual patients. Prior to this Review, Australia’s HTA had not been comprehensively reviewed in more than 30 years.
Implementing the full package of recommended reforms will ensure Australia’s HTA system evolves to keep pace with advancements in medical technologies and delivers faster patient access to new medicines.
HTA Review findings
The Review made 50 recommendations for reform that will:
1. Address inequities in access.
2. Improve timely access to medicines.
3. Improve engagement.
4. Invest in HTA capability to make it adaptable and future proof.